NSD2 and prostate cancer: Further, NSD2 expression was significantly higher in prostate cancer metastases reported in the SU2C cohort21 (n = 51) as compared with primary tumors from TCGA (n = 333; p = 1.64 × 10−10 two-sample two-tailed Welch t-test; Fig. 4c).